You opened eRA Commons. You scanned the page. And there it was.
Not discussed.
No score. No percentile. No summary of the discussion, because there was no discussion. Two words that land like a door closing — and then the silence that follows, which is the part nobody prepares you for.
I know this silence. I have sat in it as an applicant. I have contributed to it as a reviewer — participating in a process that sorts applications into tiers and sends some of them back to their investigators with no score and no explanation beyond three individual critiques. I have watched colleagues receive this designation and process it as a verdict on their science, their capacity, or their place in the field.
I want to talk about what those two words actually mean in this review cycle. Because under the modified review procedures currently in effect, “not discussed” no longer means one thing. It means two fundamentally different things. And how you respond — emotionally, strategically, professionally — depends entirely on which one applies to you.
The split you need to understand
Under the traditional review process, “not discussed” meant triaged. Bottom half. The study section decided, during the streamlining phase, that the application did not warrant the investment of discussion time. Roughly the bottom 50% of applications received this designation. It was painful, and it was unambiguous.
That clarity no longer exists.
Under the modified procedures in effect for the October 2026 Advisory Council — and for the January and May 2026 Councils before it — the study section discusses only the top 30–35% of applications. The remaining applications are sorted by committee vote into two tiers.
The middle third receives the designation “competitive but not discussed.” These applications are considered for funding alongside the discussed applications. They were strong enough that the committee recognized their merit. They were close enough that, under the traditional process, many of them would have been in the discussed half. The modified procedures moved the discussion threshold, and these applications fell on the wrong side of a line that used to be drawn in a different place.
The lowest third receives the designation “not competitive and not discussed.” This is what “not discussed” used to mean under the old system.
If you are looking at a “not discussed” designation right now, the first question — before you read a single critique, before you start thinking about resubmission, before you allow yourself to feel anything — is: which category are you in?
Your summary statement should indicate the tier. Look for the language. “Competitive but not discussed” and “not competitive and not discussed” are distinct designations, and they carry distinct implications for everything that follows.
If you are competitive but not discussed
This is the designation that the system has never had to explain before, because it did not exist before.
You are in the middle third. The committee recognized that your application has scientific merit. You are still in consideration for funding — the modified procedures explicitly state that applications in the middle third will be considered alongside the discussed applications. You do not have an overall impact score, because only discussed applications receive one. But you have a tier designation that places you above the bottom third, and you have the written critiques from your three assigned reviewers.
Here is what that means, and here is what it does not.
It means your science was in the range. The idea, the question, the significance — something in your application was strong enough that the committee did not place you in the lowest tier. In a cycle where only 30–35% of applications are discussed, being in the middle third puts you closer to the top than the bottom.
It does not mean you would have scored well if discussion had occurred. Discussion is where individual reviewer positions get tested, where scores shift, where a strong advocate can change the trajectory of an application. You did not get that chance. And there is no way to know, from the materials you have, what would have happened if you had.
That uncertainty is the hardest part of this designation. “Not competitive and not discussed” is devastating, but it is clear. You know where you stand and you know you need to rethink. “Competitive but not discussed” gives you enough hope to wonder and not enough information to know. It is, in some ways, the loneliest outcome in the system — because you were close enough that the structure mattered more than the science.
How to read your critiques from this position
You have three individual reviewer critiques. You do not have an overall impact score. You do not have a narrative Resume and Summary of Discussion. You have, in the simplified format, a sentence describing the degree of consensus in the committee vote and bullets listing the main score-driving points.
Everything I have taught in this series about reading critiques applies here — and it applies with more urgency, because you have less interpretive scaffolding than a discussed applicant receives.
The individual critiques are pre-discussion documents. They were written before any conversation occurred — and in your case, no conversation did occur. Each critique reflects one reviewer’s assessment, shaped by their own disciplinary lens, their own cognitive availability, their own interpretive frame. The length of a weakness paragraph is still not a proxy for how much it mattered. The specificity of a concern is still not a proxy for its weight.
What you need to do — and what is harder here than for a discussed application — is triangulate across the three critiques yourself. The room would have done this work for you if your application had been discussed. The room would have surfaced where the reviewers agreed and where they diverged. The room would have tested whether a concern one reviewer raised was shared by the group or was idiosyncratic. In the absence of that deliberation, you have to reconstruct the convergence from the written record.
Where do at least two of the three reviewers raise the same underlying concern? That convergence is the closest proxy you have for what the room would have said. It is the concern your resubmission needs to address first, most substantively, and most visibly — the same principle I described in the Introduction page piece, applied under conditions of less information.
Where does only one reviewer raise a concern that the other two do not mention? That may be a real issue. It may also be an idiosyncratic reading. In a discussed meeting, the room would have resolved that ambiguity. Here, you have to make a judgment call. If the concern is methodological and specific, take it seriously regardless of whether the other reviewers raised it. If it is interpretive — a disagreement about framing or emphasis — weigh it against what the other two reviewers said and decide whether it reflects a genuine misunderstanding in your application or a reviewer who read your work through a different lens.
The score-driving bullets in the simplified summary give you the topics the committee identified as most salient. These are your anchors. If a concern appears in the individual critiques and in the score-driving bullets, it is central. If it appears in a critique but not in the bullets, it is secondary. Build your resubmission hierarchy around this distinction.
If you are not competitive and not discussed
This is the designation that carries the meaning “not discussed” used to carry. The committee placed you in the lowest third. Your application is not being considered for funding in this cycle.
This is hard to read. I will not soften it.
What I will say is what I said in “The Lie of the Well-Written Grant” several weeks ago: a nonfunding decision is one outcome inside a system with variables you did not control. The study section composition. The competition density in your review cycle. The modified discussion threshold that moved the line from 50% to 30–35%. Your application operated inside all of these, and the designation you received reflects all of them — along with whatever genuine weaknesses the reviewers identified in your science.
Your job is to separate what is yours from what is the system’s. And the critiques are where that separation happens.
Read the three individual critiques the way I have described throughout this series: looking for convergence, distinguishing between structural concerns and surface-level critique points, identifying where the reviewers agreed and where they diverged. The concerns that converge across reviewers are yours to address. The concerns that appear once and contradict the other reviewers’ readings may be idiosyncratic. And concerns that are actually about the competition — “other approaches have been more thoroughly tested,” “the field has moved in a direction that makes this question less urgent” — are signals about positioning, not about your science.
A “not competitive and not discussed” outcome does not mean your science has no merit. It means that this version of this application, reviewed by these specific people, in this specific cycle, under these specific structural conditions, did not reach the threshold. Whether the next version can is a question your critiques can help you answer — if you read them with the precision this series has been building.
The emotional processing that nobody talks about
There is a professional script for receiving a “not discussed” designation. Read the critiques. Identify the weaknesses. Plan the revision. Move forward.
The script skips something important.
Before you read the critiques — and I mean this literally, before you open the document — give yourself the space to feel the weight of the outcome without converting it into a task list. The instinct to move immediately into problem-solving mode is a coping mechanism. It is a way of converting disappointment into action, which feels productive. And it often leads to reading the critiques through a lens of defensiveness or urgency that distorts what the reviewers actually said.
I have watched investigators read their summary statements within an hour of receiving them and begin drafting revision plans the same day. The plans they build in that state are almost always reactive — responding to the loudest criticism, the most painful comment, the thing that stung most on first reading. Those are rarely the structural issues that a resubmission needs to address.
The better practice — and I say this from experience, including my own — is to read the critiques once, close the document, and wait. A day. A few days. A week if you can afford it. Then read them again with the tools this series has given you: looking for the convergence, separating the room’s likely concern from the individual voices, identifying the structural issue underneath the surface-level points.
Your first reading will be emotional. It should be. You invested months of work and intellectual commitment in this application. The designation hurts because the work mattered.
Your second reading will be strategic. And the distance between those two readings is where the strongest resubmissions begin.
What the Unified Funding Strategy means for “competitive but not discussed”
There is one more dimension of this designation that bears attention, and it connects to what I described several weeks ago about the Unified Funding Strategy.
Under the UFS, IC directors consider the full content of reviewer assessments alongside mission alignment, portfolio balance, geographic distribution, career stage diversity, and urgent public health needs. The payline is no longer the organizing principle for funding decisions.
For applications that are “competitive but not discussed,” this creates a specific possibility that did not exist under the old system in the same way. Your application has no overall impact score — but it has three reviewer critiques, a tier designation, and score-driving bullets. An IC director making funding decisions under the UFS has the authority to consider your application alongside discussed ones, weighing the reviewer assessments against the strategic factors the UFS names.
This does not mean you should count on being funded without a score. The probability remains lower than for a discussed application with a strong percentile. But it means that the language in your application — the significance framing, the public health urgency, the mission alignment — may reach a decision-maker who is reading beyond the score. Everything I taught in the Significance section piece about writing for two audiences applies here with particular force: for “competitive but not discussed” applications, the second audience may be the only path to funding in this cycle.
Whether to resubmit or wait to see if funding comes through on the strength of the UFS criteria is a question your program officer can help you navigate. Contact them. This is exactly the kind of strategic conversation they are equipped to have — and under the current landscape, it is a conversation more applicants should be having.
What I want you to carry
If you are reading this with a “not discussed” designation fresh in your hands (and I speak from personal experience as I sit there right with you today), here is what I want you to hold.
The system changed around you. The discussion threshold moved. The number of applications that receive discussion dropped by a third. The structural conditions of this review cycle are different from any you have experienced before — and the designation you received exists inside those conditions.
Your science did not change when the threshold moved. Your question is still your question. Your commitment to the work is still your commitment. What changed is the architecture of the evaluation — and this series has spent months giving you the tools to navigate that architecture with precision.
Read the critiques. Find the convergence. Separate what is yours from what is the system’s. Give yourself the time to move from the emotional reading to the strategic one. And then — if the science warrants it, if the critiques point toward a path, if the question still matters to you — build the resubmission with everything this series has taught you about where the writing carries the weight.
Two words on a screen do not define your science. What you do with what comes after them might.
What is one “not discussed” outcome — or any evaluative silence — that looked different to you once you had the distance to read it again?
~Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
More insights at lisacarterbawa.com/insights
The Spring 2027 LIT Cohort opens soon, with Monday and Friday sections timed to the June 2027 NIH deadline. Each section is limited to 10 investigators. You get five live sessions, full access to the Lost In Translation (LIT) course (14 modules and 13 workbooks), and a Translation Feedback Brief: a one-on-one review of your revised Aims page or full grant, returned in time for your submission. Join the interest list for first access before enrollment opens publicly.
Want to start now? The self-paced course is available today, and what you pay for it is credited toward a cohort seat. Module 1 is free.
For cancer centers, training programs, and research-intensive departments, LIT is also offered as an institutional cohort. Write to me at lisa@soultosoulleadership.com to talk about what would serve your investigators.
